Decapeptyl SR approved for use in early puberty

The GnRH analogue Decapeptyl SR (triptorelin) has been approved for the treatment of precocious puberty starting before eight years of age in girls, and before nine years of age in boys.

The recommended dose is one intramuscular injection of Decapeptyl SR 11.25 mg every three months. Treatment should be stopped around the physiological age of puberty; for girls, a bone maturation age of more than 12 years; for boys, a bone maturation age of 13 to 14 years.

Further information: Ipsen Ltd, 190 Bath Road, Slough, Berkshire SL1 3XE. Tel: (01753) 627777.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases